{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:37:50Z","timestamp":1773283070618,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ccc.2013.06.010","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T02:17:51Z","timestamp":1376446671000},"page":"895-921","source":"Crossref","is-referenced-by-count":18,"title":["Resistant Gram-Negative Infections"],"prefix":"10.1016","volume":"29","author":[{"given":"Henry","family":"Fraimow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Nahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccc.2013.06.010_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ccc.2013.06.010_bib2","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Livermore","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2110-5820-1-47","article-title":"The rising problem of antimicrobial resistance in the intensive care unit","volume":"1","author":"Brusselaers","year":"2011","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ccc.2013.06.010_bib5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2013.06.010_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000237835","article-title":"Sensitivity of gentamicin-resistant Enterobacteriaceae to cefamandole and cefoxitin","volume":"25","author":"Rosenthal","year":"1979","journal-title":"Chemotherapy"},{"issue":"1","key":"10.1016\/j.ccc.2013.06.010_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/bi3014714","article-title":"Unilateral access regulation: ground state dynamics of the Pseudomonas aeruginosa outer membrane efflux duct OprM","volume":"52","author":"Koch","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ccc.2013.06.010_bib8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccc.2010.11.002","article-title":"Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens","volume":"27","author":"Fraimow","year":"2011","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ccc.2013.06.010_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ccc.2013.06.010_bib10","unstructured":"Pillar CM, Brown NP, Sahm DF, et\u00a0al. Trends towards increased resistance among clinically important gram-negative pathogens in the US; results from 10 years of TRUST surveillance (1999-2009). Abstract C2-696, Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston (MA): 2010. Available at: http:\/\/www.eurofins.com\/media\/1770121\/C2-696.pdf. Accessed January 23, 2013."},{"key":"10.1016\/j.ccc.2013.06.010_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijantimicag.2010.09.001","article-title":"Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"36","author":"Yang","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ccc.2013.06.010_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/652152","article-title":"Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008","volume":"31","author":"Kallen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ccc.2013.06.010_bib13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1128\/AAC.01538-07","article-title":"Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006","volume":"52","author":"Zhanel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajic.2011.05.020","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009","volume":"40","author":"Rosenthal","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ccc.2013.06.010_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajic.2011.05.022","article-title":"Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospitalized patients initially only colonized with carbapenem resistant K. pneumoniae","volume":"40","author":"Borer","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ccc.2013.06.010_bib16","unstructured":"Available at: http:\/\/www.cdc.gov\/hai\/eip\/mugsi_techinfo.html. Accessed January 23, 2013."},{"key":"10.1016\/j.ccc.2013.06.010_bib17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1099\/jmm.0.46747-0","article-title":"The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"55","author":"Falagas","year":"2006","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.ccc.2013.06.010_bib18","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1469-0691.2003.00690.x","article-title":"Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group","volume":"9","author":"Goossens","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1086\/528867","article-title":"Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: need for international harmonization in terminology","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/591134","article-title":"A\u00a0multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study","volume":"47","author":"Apisarnthanarak","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3201\/eid1506.081006","article-title":"Extensively drug-resistant Acinetobacter baumannii","volume":"15","author":"Doi","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3201\/eid1508.080772","article-title":"Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea","volume":"15","author":"Park","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.ccc.2013.06.010_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib24","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement CLSI document M100-S20. Wayne (PA): Clinical and Laboratory Standards Institute."},{"issue":"9","key":"10.1016\/j.ccc.2013.06.010_bib25","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.06365-11","article-title":"Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification","volume":"56","author":"Esterly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ccc.2013.06.010_bib26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1128\/AAC.00580-08","article-title":"Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin","volume":"53","author":"Defife","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib27","first-page":"28","article-title":"Treatment options for infections caused by carbapenem-resistant gram negative bacteria","volume":"6","author":"Kosmidis","year":"2012","journal-title":"Eur Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ccc.2007.12.003","article-title":"Colistin and polymyxin B in critical care","volume":"24","author":"Michalopoulos","year":"2008","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ccc.2013.06.010_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/cid\/cis863","article-title":"Editorial commentary: saving lives with optimal antimicrobial chemotherapy","volume":"56","author":"Drusano","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and Piperacillin\/Tazobactam: a systematic review and meta-analysis","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1586\/eri.11.126","article-title":"Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia","volume":"9","author":"Wood","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ccc.2013.06.010_bib32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1378\/chest.130.3.787","article-title":"Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia","volume":"130","author":"Beardsley","year":"2006","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.ccc.2013.06.010_bib33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/599809","article-title":"Doripenem: a new carbapenem in the treatment of nosocomial infection","volume":"49","author":"Mandell","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib34","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1128\/AAC.01768-09","article-title":"In\u00a0vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli","volume":"54","author":"Urban","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2010.04.002","article-title":"In\u00a0vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008","volume":"68","author":"Wang","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijantimicag.2009.01.015","article-title":"Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint","volume":"34","author":"Burkhardt","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ccc.2013.06.010_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: an old\u2013new antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.01097-08","article-title":"In\u00a0vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group","volume":"53","author":"Arroyo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/IPC.0b013e318245d50a","article-title":"A\u00a0stewardship approach to combating multidrug-resistant Acinetobacter infections with minocycline","volume":"20","author":"Jankowski","year":"2012","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"10.1016\/j.ccc.2013.06.010_bib42","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ccc.2013.06.010_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/653120","article-title":"Treatment of Acinetobacter infections","volume":"51","author":"Fishbain","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib44","first-page":"263","article-title":"New Delhi metallo-beta-lactamase (NDM-1): an update","volume":"23","author":"Shakil","year":"2011","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijantimicag.2009.08.011","article-title":"Rifampicin combined regimens for gram-negative infections: data from the literature","volume":"35","author":"Drapeau","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ccc.2013.06.010_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1469-0691.2011.03734.x","article-title":"Colistin: new lessons on an old antibiotic","volume":"18","author":"Yahav","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QCO.0b013e328332e672","article-title":"Colistin in the 21st century","volume":"22","author":"Nation","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib48","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dks084","article-title":"Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies","volume":"67","author":"Cai","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib49","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drup.2011.02.003","article-title":"Critical shortage of new antibiotics in development against multidrug-resistant bacteria\u2014time to react is now","volume":"14","author":"Freire-Moran","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ccc.2013.06.010_bib51","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/cid\/cir934","article-title":"What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression","volume":"54","author":"Florescu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib52","unstructured":"Trial for the treatment of extensively drug-resistant gram-negative bacilli. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597973. Accessed January 24, 2013."},{"key":"10.1016\/j.ccc.2013.06.010_bib53","unstructured":"Multicenter open-label randomized controlled trial (RCT) to compare colistin alone versus colistin plus meropenem. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01732250. Accessed January 24, 2013."},{"key":"10.1016\/j.ccc.2013.06.010_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/2110-5820-2-37","article-title":"Continuous beta-lactam infusion in critically ill patients: the clinical evidence","volume":"2","author":"Abdul-Aziz","year":"2012","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ccc.2013.06.010_bib55","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2146\/ajhp110562","article-title":"National survey on continuous and extended infusions of antibiotics","volume":"69","author":"George","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccc.2013.06.010_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib57","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/sur.2006.051","article-title":"Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study","volume":"8","author":"Hallal","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ccc.2013.06.010_bib59","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1592\/phco.29.9.1054","article-title":"Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia","volume":"29","author":"Czosnowski","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2013.06.010_bib60","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/sur.2006.041","article-title":"Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia","volume":"8","author":"Mohr","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ccc.2013.06.010_bib61","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1086\/657242","article-title":"Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study","volume":"51","author":"Kofteridis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib63","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccc.2013.06.010_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","article-title":"Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices","volume":"70","author":"Pitout","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ccc.2013.06.010_bib65","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib66","doi-asserted-by":"crossref","first-page":"831","DOI":"10.47102\/annals-acadmedsg.V37N10p831","article-title":"Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia","volume":"37","author":"Lye","year":"2008","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ccc.2013.06.010_bib67","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.diagmicrobio.2006.03.019","article-title":"Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Labombardi","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diagmicrobio.2006.06.015","article-title":"Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli","volume":"56","author":"Bin","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib72","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1128\/AAC.46.5.1481-1491.2002","article-title":"Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome","volume":"46","author":"Kim","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccc.2013.06.010_bib74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ccc.2013.06.010_bib75","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ccc.2013.06.010_bib76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","article-title":"Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections","volume":"18","author":"Ben-David","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/649865","article-title":"An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes","volume":"50","author":"Souli","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","author":"Daikos","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib79","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1086\/600042","article-title":"Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature","volume":"49","author":"Elemam","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib80","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dki175","article-title":"Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in\u00a0vitro activity of polymyxin B and other agents","volume":"56","author":"Bratu","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib81","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1128\/JCM.01106-10","article-title":"In\u00a0vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae","volume":"48","author":"Elemam","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ccc.2013.06.010_bib82","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/cid\/cis385","article-title":"Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection","volume":"55","author":"Lee","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib84","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkr239","article-title":"Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09)","volume":"66","author":"Gales","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/0974-777X.68538","article-title":"Multidrug resistant Acinetobacter","volume":"2","author":"Manchanda","year":"2010","journal-title":"J\u00a0Glob Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib86","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/600036","article-title":"Doripenem","volume":"49","author":"Paterson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib87","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1592\/phco.27.11.1506","article-title":"Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in\u00a0vitro combination synergy study","volume":"27","author":"Lee","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2013.06.010_bib88","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/374337","article-title":"Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP","volume":"36","author":"Garnacho-Montero","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib89","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib90","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00922-10","article-title":"Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii","volume":"54","author":"Gordon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib91","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1469-0691.2008.02061.x","article-title":"Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies","volume":"14","author":"Petrosillo","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib92","first-page":"273","article-title":"Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens","volume":"58","author":"Poulakou","year":"2009","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.ccc.2013.06.010_bib93","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1016\/j.ijid.2009.06.032","article-title":"Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature","volume":"14","author":"Cascio","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib94","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1128\/AAC.00207-10","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes","volume":"54","author":"Tam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ccc.2013.06.010_bib95","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-012-1741-4","article-title":"Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands","volume":"32","author":"Croughs","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib96","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/jac\/dkr232","article-title":"Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem","volume":"66","author":"Riera","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib97","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2169\/internalmedicine.50.4270","article-title":"Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis","volume":"50","author":"Durakovic","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.ccc.2013.06.010_bib98","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkq390","article-title":"Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia","volume":"66","author":"Kvitko","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib99","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/mdr.2010.0145","article-title":"Identification of nonclonal Pseudomonas aeruginosa isolates with reduced colistin susceptibility in Korea","volume":"17","author":"Lee","year":"2011","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ccc.2013.06.010_bib100","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/AAC.47.9.2756-2764.2003","article-title":"Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia","volume":"47","author":"Chamot","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib101","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1086\/657249","article-title":"Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia","volume":"51","author":"Apisarnthanarak","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10096-007-0279-3","article-title":"Antimicrobial therapy for Stenotrophomonas maltophilia infections","volume":"26","author":"Nicodemo","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ccc.2013.06.010_bib103","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/dkl496","article-title":"In\u00a0vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia","volume":"59","author":"Insa","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ccc.2013.06.010_bib104","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1097\/01.CCM.0000143119.41916.5D","article-title":"Source control in the management of severe sepsis and septic shock: an evidence-based review","volume":"32","author":"Marshall","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ccc.2013.06.010_bib105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/bja\/aeq276","article-title":"Mechanical thrombectomy of an infected deep venous thrombosis: a novel technique of source control in sepsis","volume":"106","author":"Sulaiman","year":"2011","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ccc.2013.06.010_bib106","unstructured":"Rennie RP, Turnbull L, Johnson A. Surveillance of gram-negative intra-abdominal and urinary tract pathogens in Canada compared to the rest of the world: the SMART study Abstract C2-1789, Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL): 2011."}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070413000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070413000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T21:10:41Z","timestamp":1688418641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070413000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0749070413000626"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2013.06.010","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}